Market Overview

NuProbe Forms Scientific Advisory Board and Appoints New Director


, an early stage molecular diagnostics company, announced
today the formation of its Scientific Advisory Board (SAB) with genomics
pioneers George M. Church, Ph.D., Professor of Genetics at Harvard
Medical School
, and David R. Walt, Ph.D., Professor of Pathology at
Harvard Medical School. The SAB will help to guide the company's
strategy and advance its technology platform. It is also expanding its
Board of Directors with the addition of veteran healthcare investor
Kevin Chen, Founding Partner at Biotrack Capital.

"The success of many therapies and the possibility to prevent surgeries
will rely on the availability of strong diagnostic capabilities to
detect diseases at an early stage," said Dr. Church, who has a
successful track record of developing and transferring technologies to
more than 15 biotech companies including AbVitro (acquired by Juno),
Editas Medicine, and eGenesis. "NuProbe's technology has the potential
to provide disruptive solutions toward this aim."

NuProbe's toehold probe-based platform technology enhances qPCR and NGS
mutation detection sensitivity and multiplexing capability. This opens
the possibility for ultra-sensitive and non-invasive blood tests to
improve detection of cancer and infectious diseases and help guide
treatment decisions.

"NuProbe's technology could expand the reach of non-invasive molecular
diagnostics and bring us closer to realizing the potential of precision
medicine," said Dr. Walt, who is also the Scientific Founder of Illumina
and Quanterix, and co-founder of several other life science companies
including Ultivue.

"We are fortunate to have Dr. Church and Dr. Walt join NuProbe's SAB,"
said Peng Yin, Ph.D., who together with David Yu Zhang, Ph.D., and
Victor Shi, Ph.D., co-founded NuProbe. "Being able to leverage their
unparalleled knowledge and experience will be instrumental in moving our
molecular diagnostic tests forward into the clinic."

Dr. Yin is also Professor of Systems Biology at Harvard Medical School
and Core Faculty member of the Wyss Institute. Dr. Zhang is the Ted Law
Jr. Assistant Professor of Bioengineering at Rice University. Dr. Shi is
NuProbe's CEO.

With the appointment of Kevin Chen to NuProbe's Board of Directors, the
company is adding further industry expertise. Mr. Chen has led
investments in over 20 leading healthcare companies including Beijing
Genomics Institute (BGI), Betta Pharma, and Yuwell Medical. "I'm excited
to work with NuProbe to help expand its role as a global molecular
diagnostics company with growing operations in the United States and in
China" said Mr. Chen.

"We are very pleased to have Kevin Chen join our Board as he brings a
tremendous wealth of experience from the healthcare industry to NuProbe
to help pave the way for an impactful diagnostic portfolio," said Dr.

NuProbe was established in 2016 and has operations in Cambridge, MA and
China. Its investors
include Sequoia Capital China, Serica Partners and WuXi AppTec Corporate

George M. Church, Ph.D., is a Professor of Genetics at Harvard
Medical School, a Professor of Health Sciences and Technology at Harvard
and MIT, and a Founding Member of the Wyss Institute for Biologically
Inspired Engineering at Harvard. Dr. Church is also Director of the U.S.
Department of Energy Technology Center, Director of the National
Institutes of Health Center of Excellence in Genomic Science, and
Director of the Personal Genome Project. He is the co-founder of more
than 15 biotech companies including AbVitro, Editas Medicine, Veritas
Genetics, Warpdrive Bio, eGenesis and ReadCoor. He is a member of the
National Academy of Sciences, the National Academy of Engineering and
the Franklin Bower Laureate for Achievement in Science. He received a
B.A. in Zoology and Chemistry from Duke University and a Ph.D. in
Biochemistry and Molecular Biology from Harvard University.

David R. Walt, Ph.D., is a member of the faculty at Harvard
Medical School in the Department of Pathology at Brigham and Women's
Hospital, is a Member of the Wyss Institute, and is a Howard Hughes
Medical Institute Professor. Previously, he was University Professor at
Tufts University. Dr. Walt is the Scientific Founder of Illumina and
Quanterix and has co-founded several other life sciences startups
including Ultivue and Arbor Biotechnologies. He is a member of the
National Academy of Engineering, the National Academy of Medicine, a
Fellow of the American Academy of Arts and Sciences, a Fellow of the
American Institute for Medical and Biological Engineering, and a Fellow
of the National Academy of Inventors. He received a B.S. in Chemistry
from the University of Michigan and a Ph.D. in Chemical Biology from
SUNY at Stony Brook.

Kevin (Penghui) Chen is a Founding Partner at Biotrack Capital.
Previously, he was a Partner at Sequoia Capital China, responsible for
healthcare investment. Before Sequoia Capital, Mr. Chen set up the first
healthcare fund at Everbright Holdings and served as Head of Everbright
Healthcare Fund. He has led investments in over 20 leading healthcare
companies in China, including the Beijing Genomics Institute (BGI),
Betta Pharma, Yuwell Medical, Zai Lab, and Amcare Hospital. Before
Everbright, Mr. Chen served as President of ShangPharma, a leading China
CRO company, and was the COO and CFO of ShangPharma and took the company
public at NYSE in 2010. He received a B.S. in Chemistry from Nanjing
University, a M.S. in Medicinal Chemistry from Tulane University, and an
MBA from Kellogg School of Management, Northwestern University.

About NuProbe
NuProbe's vision is to pioneer technology
innovation to advance human health. Its technology enables precise and
comprehensive capturing of disease signatures with uniquely high
sensitivity and multiplexing capability. The proprietary and patented
technology is compatible with common PCR and sequencing platforms, and
clinical workflow. NuProbe develops multiple platforms for diverse
molecular diagnostics applications, including cancer, non-invasive
prenatal testing (NIPT), and infectious disease. To learn more, visit

View Comments and Join the Discussion!